Cargando…
Novel 1 L polyethylene glycol-based bowel preparation (NER1006): proof of concept assessment versus standard 2 L polyethylene glycol with ascorbate – a randomized, parallel group, phase 2, colonoscopist-blinded trial
BACKGROUND: Colonoscopy requires colon cleansing. For this, many polyethylene glycol (PEG)-based preparations still require a high preparation-volume intake. Using an increased osmotic load with ascorbate (Asc), five new low-volume PEG-based bowel preparations (LVPEG) were tested for clinical proof...
Autores principales: | , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2019
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6543558/ https://www.ncbi.nlm.nih.gov/pubmed/31146679 http://dx.doi.org/10.1186/s12876-019-0988-y |
_version_ | 1783423098896252928 |
---|---|
author | Clayton, Lucy B. Tayo, Bola Halphen, Marc Kornberger, Rüdiger |
author_facet | Clayton, Lucy B. Tayo, Bola Halphen, Marc Kornberger, Rüdiger |
author_sort | Clayton, Lucy B. |
collection | PubMed |
description | BACKGROUND: Colonoscopy requires colon cleansing. For this, many polyethylene glycol (PEG)-based preparations still require a high preparation-volume intake. Using an increased osmotic load with ascorbate (Asc), five new low-volume PEG-based bowel preparations (LVPEG) were tested for clinical proof of concept. METHODS: This two-part, open-label study examined preparation-volumes of 1–1.25 L and total required fluid volumes of 2–3 L. Part 1, in healthy volunteers, used mean cumulative 24-h stool weight (target > 2750 g) to identify a lead candidate. Part 2 was endoscopist-blinded: patients undergoing screening colonoscopy were randomized before treatment with the selected lead, one of two variants of it, or the control 2 L PEG + Asc. Two primary endpoints were used for proof of concept demonstration: mean 24-h stool weight and bowel cleansing success (Harefield Cleansing Scale). RESULTS: A total of 120 subjects (30 per group) were enrolled/randomized 1:1:1:1 (max 40:60 gender ratio) per completed Part. In Part 1, LVPEG-3 achieved the largest mean stool weight (3399 g: P < 0.0001 vs target) and was selected for Part 2. In Part 2, stool weights exceeded the target, notably for LVPEG-4 (3215 g: P < 0.001), which achieved 100% cleansing success after a total required fluid intake of 2 L. The control achieved 90% cleansing success. Adverse events were few, gastrointestinal in nature and similar between groups. CONCLUSIONS: LVPEG-4 achieved a clinically useful combination of cleansing, safety/tolerability and low consumption volume: 1 L preparation + 1 L required additional fluid. Named NER1006, LVPEG-4 demonstrated clinical proof of concept and warrants further investigation. TRIAL REGISTRATION: October 2012. Identifier: NCT01714466. EudraCT: 2012–003052-37 The trial was prospectively registered. ELECTRONIC SUPPLEMENTARY MATERIAL: The online version of this article (10.1186/s12876-019-0988-y) contains supplementary material, which is available to authorized users. |
format | Online Article Text |
id | pubmed-6543558 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2019 |
publisher | BioMed Central |
record_format | MEDLINE/PubMed |
spelling | pubmed-65435582019-06-04 Novel 1 L polyethylene glycol-based bowel preparation (NER1006): proof of concept assessment versus standard 2 L polyethylene glycol with ascorbate – a randomized, parallel group, phase 2, colonoscopist-blinded trial Clayton, Lucy B. Tayo, Bola Halphen, Marc Kornberger, Rüdiger BMC Gastroenterol Research Article BACKGROUND: Colonoscopy requires colon cleansing. For this, many polyethylene glycol (PEG)-based preparations still require a high preparation-volume intake. Using an increased osmotic load with ascorbate (Asc), five new low-volume PEG-based bowel preparations (LVPEG) were tested for clinical proof of concept. METHODS: This two-part, open-label study examined preparation-volumes of 1–1.25 L and total required fluid volumes of 2–3 L. Part 1, in healthy volunteers, used mean cumulative 24-h stool weight (target > 2750 g) to identify a lead candidate. Part 2 was endoscopist-blinded: patients undergoing screening colonoscopy were randomized before treatment with the selected lead, one of two variants of it, or the control 2 L PEG + Asc. Two primary endpoints were used for proof of concept demonstration: mean 24-h stool weight and bowel cleansing success (Harefield Cleansing Scale). RESULTS: A total of 120 subjects (30 per group) were enrolled/randomized 1:1:1:1 (max 40:60 gender ratio) per completed Part. In Part 1, LVPEG-3 achieved the largest mean stool weight (3399 g: P < 0.0001 vs target) and was selected for Part 2. In Part 2, stool weights exceeded the target, notably for LVPEG-4 (3215 g: P < 0.001), which achieved 100% cleansing success after a total required fluid intake of 2 L. The control achieved 90% cleansing success. Adverse events were few, gastrointestinal in nature and similar between groups. CONCLUSIONS: LVPEG-4 achieved a clinically useful combination of cleansing, safety/tolerability and low consumption volume: 1 L preparation + 1 L required additional fluid. Named NER1006, LVPEG-4 demonstrated clinical proof of concept and warrants further investigation. TRIAL REGISTRATION: October 2012. Identifier: NCT01714466. EudraCT: 2012–003052-37 The trial was prospectively registered. ELECTRONIC SUPPLEMENTARY MATERIAL: The online version of this article (10.1186/s12876-019-0988-y) contains supplementary material, which is available to authorized users. BioMed Central 2019-05-30 /pmc/articles/PMC6543558/ /pubmed/31146679 http://dx.doi.org/10.1186/s12876-019-0988-y Text en © The Author(s). 2019 Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated. |
spellingShingle | Research Article Clayton, Lucy B. Tayo, Bola Halphen, Marc Kornberger, Rüdiger Novel 1 L polyethylene glycol-based bowel preparation (NER1006): proof of concept assessment versus standard 2 L polyethylene glycol with ascorbate – a randomized, parallel group, phase 2, colonoscopist-blinded trial |
title | Novel 1 L polyethylene glycol-based bowel preparation (NER1006): proof of concept assessment versus standard 2 L polyethylene glycol with ascorbate – a randomized, parallel group, phase 2, colonoscopist-blinded trial |
title_full | Novel 1 L polyethylene glycol-based bowel preparation (NER1006): proof of concept assessment versus standard 2 L polyethylene glycol with ascorbate – a randomized, parallel group, phase 2, colonoscopist-blinded trial |
title_fullStr | Novel 1 L polyethylene glycol-based bowel preparation (NER1006): proof of concept assessment versus standard 2 L polyethylene glycol with ascorbate – a randomized, parallel group, phase 2, colonoscopist-blinded trial |
title_full_unstemmed | Novel 1 L polyethylene glycol-based bowel preparation (NER1006): proof of concept assessment versus standard 2 L polyethylene glycol with ascorbate – a randomized, parallel group, phase 2, colonoscopist-blinded trial |
title_short | Novel 1 L polyethylene glycol-based bowel preparation (NER1006): proof of concept assessment versus standard 2 L polyethylene glycol with ascorbate – a randomized, parallel group, phase 2, colonoscopist-blinded trial |
title_sort | novel 1 l polyethylene glycol-based bowel preparation (ner1006): proof of concept assessment versus standard 2 l polyethylene glycol with ascorbate – a randomized, parallel group, phase 2, colonoscopist-blinded trial |
topic | Research Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6543558/ https://www.ncbi.nlm.nih.gov/pubmed/31146679 http://dx.doi.org/10.1186/s12876-019-0988-y |
work_keys_str_mv | AT claytonlucyb novel1lpolyethyleneglycolbasedbowelpreparationner1006proofofconceptassessmentversusstandard2lpolyethyleneglycolwithascorbatearandomizedparallelgroupphase2colonoscopistblindedtrial AT tayobola novel1lpolyethyleneglycolbasedbowelpreparationner1006proofofconceptassessmentversusstandard2lpolyethyleneglycolwithascorbatearandomizedparallelgroupphase2colonoscopistblindedtrial AT halphenmarc novel1lpolyethyleneglycolbasedbowelpreparationner1006proofofconceptassessmentversusstandard2lpolyethyleneglycolwithascorbatearandomizedparallelgroupphase2colonoscopistblindedtrial AT kornbergerrudiger novel1lpolyethyleneglycolbasedbowelpreparationner1006proofofconceptassessmentversusstandard2lpolyethyleneglycolwithascorbatearandomizedparallelgroupphase2colonoscopistblindedtrial |